---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Drug interactions questions"
description: "Drug interactions questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Ubrelvy have? How much do CYP3A4 inhibitors like ketoconazole raise Ubrelvy levels? Can Ubrelvy be taken with CYP3A4 inducers like rifampin or St. John's Wort? Do P-gp or BCRP inhibitors like carvedilol or quinidine affect Ubrelvy? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Drug interactions questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Drug interactions

<a id="ubrelvy-drug-interactions"></a>

### What drug interactions does Ubrelvy have?

> “UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they will cause an increase in UBRELVY exposure<sup>1</sup>
> Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of UBRELVY exposure<sup>1</sup>
> Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications. See Section 2.2 of the Prescribing Information<sup>1</sup>
> Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice; avoid second dose within 24 hours<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=UBRELVY%20should%20not%20be%20used,avoid%20second%20dose%20within%2024)

> “Table 1: Dose Modifications for Drug Interactions and for Specific Populations 
> Dosage Modifications 
>
> Initial Dose 
>
> Second Dose<sup>a</sup> 
> (if needed) 
> Concomitant Drug [see Drug Interactions (7)] 
>        Moderate CYP3A4 Inhibitors (7.1) 
> 50 mg 
> Avoid within 
> 24 hours 
>        Weak CYP3A4 Inhibitors (7.1) 
> 50 mg 
> 50 mg 
>        Strong CYP3A4 Inducers (7.2) 
> Avoid concomitant use 
>        Weak & Moderate CYP3A4 Inducers (7.2) 
> 100 mg 
> 100 mg 
>        BCRP and/or P-gp only Inhibitors (7.3) 
> 50 mg 
> 50 mg”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

> “<sup>a</sup> Second dose may be taken at least 2 hours after the initial dose”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

Note: In the Table 1 rows, the first value is the initial dose and the second is the second dose, if needed.

<a id="ubrelvy-cyp3a4-inhibitors"></a>

### How much do CYP3A4 inhibitors like ketoconazole raise Ubrelvy levels?

> “Co-administration of UBRELVY with ketoconazole, a strong CYP3A4 inhibitor, resulted in a 
> significant increase in exposure of ubrogepant [see Clinical Pharmacology (12.3)]. UBRELVY 
> should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, 
> clarithromycin) [see Contraindications (4)].   
> Co-administration of UBRELVY with verapamil, a moderate CYP3A4 inhibitor, resulted in an 
> increase in ubrogepant exposure [see Clinical Pharmacology (12.3)]. Dose adjustment is 
> recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., 
> cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and 
> Administration (2.2)]. 
> No dedicated drug interaction study was conducted with ubrogepant and weak CYP3A4 
> inhibitors. Dose adjustment is recommended with concomitant use of UBRELVY with weak 
> CYP3A4 inhibitors [see Dosage and Administration (2.2)].”

Source: [UBRELVY: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=5)

> “Co-administration of UBRELVY with ketoconazole, a strong CYP3A4 inhibitor, resulted in a 
> 9.7-fold and 5.3-fold increase in AUCinf and Cmax of ubrogepant, respectively. Co-administration”

Source: [UBRELVY: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=10)

> “of UBRELVY with verapamil, a moderate CYP3A4 inhibitor, resulted in about 3.5-fold and 2.8-
> fold increase in AUCinf and Cmax of ubrogepant, respectively. No dedicated drug interaction study 
> was conducted to assess concomitant use with weak CYP3A4 inhibitors. The conservative 
> prediction of the maximal potential increase in ubrogepant exposure with weak CYP3A4 
> inhibitors is not expected to be more than 2-fold.”

Source: [UBRELVY: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=11)

Note: The sentence at the end of the second passage continues on the next page of the label, in the third passage.

<a id="ubrelvy-cyp3a4-inducers"></a>

### Can Ubrelvy be taken with CYP3A4 inducers like rifampin or St. John's Wort?

> “Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in a 
> significant reduction in ubrogepant exposure [see Clinical Pharmacology (12.3)]. In patients 
> taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John’s Wort), loss of 
> ubrogepant efficacy is expected, and concomitant use should be avoided. 
> Co-administration of UBRELVY with moderate or weak CYP3A4 inducers was not evaluated in 
> a clinical study. Dose adjustment is recommended with concomitant use of UBRELVY and 
> moderate or weak CYP3A4 inducers [see Dosage and Administration (2.2)].”

Source: [UBRELVY: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=5)

> “Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in an 80% 
> reduction in ubrogepant exposure. No dedicated drug interaction studies were conducted to 
> assess concomitant use with weak or moderate CYP3A4 inducers. Dose adjustment for 
> concomitant use of UBRELVY with weak or moderate CYP3A4 inducers is recommended based 
> on a conservative prediction of 50% reduction in exposure of ubrogepant.”

Source: [UBRELVY: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=11)

<a id="ubrelvy-p-gp-bcrp-inhibitors"></a>

### Do P-gp or BCRP inhibitors like carvedilol or quinidine affect Ubrelvy?

> “Ubrogepant is a substrate of BCRP and P-gp efflux transporters. Use of BCRP and/or P-gp only 
> inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of 
> ubrogepant [see Clinical Pharmacology (12.3)]. Clinical drug interaction studies with inhibitors”

Source: [UBRELVY: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=5)

> “of these transporters were not conducted. Dose adjustment is recommended with BCRP and/or P-
> gp only inhibitors [see Dosage and Administration (2.2)].”

Source: [UBRELVY: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=6)

Note: The sentence at the end of the first passage continues on the next page of the label, in the second passage.

<a id="ubrelvy-grapefruit"></a>

### Can you have grapefruit juice with Ubrelvy?

> “Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice; avoid second dose within 24 hours<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=Dose%20adjustment%20is%20recommended%20with,avoid%20second%20dose%20within%2024)

> “Advise patients to inform their healthcare provider of grapefruit juice intake because a 
> dosage modification is recommended with co-administration.”

Source: [UBRELVY: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=15)

> “You should not take a second tablet within 24 hours if you consume grapefruit or grapefruit juice or are taking 
> medications that may include: 
> o verapamil 
> o cyclosporine 
> o ciprofloxacin 
> o fluconazole 
> o fluvoxamine”

Source: [UBRELVY: Prescribing information, page 16, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=16)

Note: The last passage is from the Patient Information printed with the Prescribing Information.

<a id="ubrelvy-birth-control-other-migraine-drugs"></a>

### Does Ubrelvy interact with birth control pills or other migraine medicines?

> “No significant pharmacokinetic interactions were observed for either ubrogepant or co-
> administered drugs when UBRELVY was administered with oral contraceptives (containing 
> norgestimate and ethinyl estradiol), acetaminophen, naproxen, sumatriptan, esomeprazole, 
> erenumab, galcanezumab, or atogepant.”

Source: [UBRELVY: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=11)

Note: These are pharmacokinetic interaction study results from the Clinical Pharmacology section of the label.

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
